Novel RNAVaccine Report: A Case Report of COVID-19 MRNA Vaccine Induced
Immune Thrombocytopenic Purpura
- Oladipo Cole
, - Vinodhini Arjunan,
- Zackary Franzen,
- Sarah Rabinowitz,
- Nabil Benhayoun
Abstract
We describe a 74-year-old female who presented with thrombocytopenia 20
days after receiving her first dose of the novel mRNA vaccine. After an
exhaustive workup, Immune Thrombocytopenia was diagnosed secondary to
her recent mRNA vaccine administration. She was treated aggressively
with high-dose steroids and IVIG, with adequate response.26 Jun 2021Submitted to Clinical Case Reports 10 Jul 2021Submission Checks Completed
10 Jul 2021Assigned to Editor
11 Jul 2021Reviewer(s) Assigned
22 Jul 2021Review(s) Completed, Editorial Evaluation Pending
29 Jul 2021Editorial Decision: Revise Minor
